natgillin/translations-raw huggingface dataset:
In the body, temsirolimus attaches to a protein inside cells to make a ‘complex'. 
Temsirolimus se v telesu veže na beljakovino v celicah in z njo tvori „kompleks“.
Torisel is used in adults when the lymphoma has come back after previous treatment or if other treatments have not worked. 
Zdravilo Torisel se uporablja pri odraslih, pri katerih se je limfom ponovil po predhodnem zdravljenju ali če druga zdravljenja niso bila učinkovita.
Torisel must not be used in patients with mantle cell lymphoma who have moderate or severe problems with their liver. 
Jemanje zdravila Torisel ni priporočljivo za bolnike z limfomom plaščnih celic, ki imajo zmerne ali hude težave z jetri.
The most common side effects with Torisel (which may affect more than 1 in 5 patients) include infections, pneumonia (infection of the lungs), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), decreased appetite, hyperglycaemia (high blood sugar levels), hypercholesterolaemia (high blood cholesterol levels), dysgeusia (taste disturbances), difficulty breathing, nose bleeds, cough, vomiting, stomatitis (inflammation of the lining of the mouth), diarrhoea, nausea (feeling sick), rash, pruritus (itching), oedema (swelling), tiredness, weakness, fever and mucosal inflammation (inflammation of moist body surfaces). 
Najpogostejši neželeni učinki zdravila Torisel (ki lahko prizadenejo več kot enega od petih bolnikov) so okužbe, pljučnica (okužba pljuč), trombocitopenija (nizka raven trombocitov), anemija (nizka raven rdečih krvničk), zmanjšanje teka, hiperglikemija (visoke ravni sladkorja v krvi), hiperholesterolemija (visoke ravni holesterola v krvi), disgevzija (motnje okusa), oteženo dihanje, krvavenje iz nosu, kašelj, bruhanje, stomatitis (vnetje ustne sluznice), diareja, navzeja (slabost), izpuščaj, pruritus (srbenje), edem (oteklina), utrujenost, oslabelost, povišana telesna temperatura in vnetje sluznic.
Patients receiving Torisel alone survived 10.9 months on average compared with 7.3 months in those receiving interferon alfa alone. 
Bolniki, ki so prejemali zdravilo Torisel samostojno, so v povprečju živeli 10,9 meseca v primerjavi s 7,3 meseca pri tistih, ki so prejemali samo interferon alfa.
Torisel must not be used in people who are hypersensitive (allergic) to temsirolimus, to its metabolites (the substances that it is broken down into) including sirolimus (a medicine used to prevent rejection of transplanted kidneys), to polysorbate 80 or to any of the other ingredients of the medicine. 
Zdravila Torisel ne smejo jemati osebe, ki so preobčutljive za (alergične na) temsirolimus, na njegove presnovke (snovi, v katere se razgradi), vključno s sirolimusom (zdravilom za preprečevanje zavrnitve presajenih ledvic), na polisorbat 80 ali katero koli drugo sestavino zdravila.
For renal cell carcinoma, the recommended dose of Torisel is 25 mg once a week, but a 10-mg dose is recommended in patients with severe liver problems who have high levels of platelets in the blood. 
Pri karcinomu ledvičnih celic je priporočeni odmerek zdravila Torisel 25 mg enkrat na teden, vendar se pri bolnikih s hudimi težavami z jetri, ki imajo visoke ravni trombocitov v krvi, priporoča 10
In advanced renal cell carcinoma, a main study involving 626 patients with poor prognosis found Torisel more effective than interferon alfa (another medicine used in the treatment of cancer) at prolonging patients' survival. 
Pri napredovalem karcinomu ledvičnih celic se je zdravilo Torisel v glavni študiji pri 626 bolnikih s slabo prognozo izkazalo za učinkovitejše od interferona alfa (drugega zdravila za zdravljenje raka) pri podaljšanju časa preživetja bolnikov.
Torisel contains the active substance temsirolimus. 
Zdravilo Torisel vsebuje zdravilno učinkovino temsirolimus.
How does Torisel work? 
Kako zdravilo Torisel deluje?
Torisel is available as a concentrate and solvent that are made up into a solution for infusion (drip) into a vein. 
Zdravilo Torisel je na voljo v obliki koncentrata in vehikla za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
Patients receiving the lower dose of Torisel in combination with interferon alfa survived for a similar time (8.4 months) as those taking interferon alfa alone. 
Pri bolnikih, ki so prejemali nižji odmerek zdravila Torisel v kombinaciji z interferonom alfa, je bil čas preživetja podoben (8,4 meseca) kot pri tistih, ki so jemali samo interferon alfa.
In mantle cell lymphoma, Torisel was found more effective than alternative cancer medicines (such as gemcitabine or fludarabine) in a main study involving 162 patients whose disease had come back after previous treatment or in whom other treatments had not worked. 
Pri limfomu plaščnih celic se je zdravilo Torisel izkazalo za učinkovitejše od alternativnih zdravila proti raku (kot sta gemcitabin ali fludarabin) v glavni študiji pri 162 bolnikih, pri katerih se je bolezen po predhodnem zdravljenju ponovila ali pri njih drugo zdravljenje ni bilo učinkovito.
The most serious side effects of Torisel are allergic (hypersensitivity) reactions, serious reactions that occur during the infusion or soon afterwards, infections, lung disorders including pneumonitis (inflammation of the lungs) and pulmonary embolism (blood clot in the lung), bleeding in the brain, kidney failure, tearing (perforation) of the intestine, complications affecting the healing of wounds, hyperglycaemia (high blood sugar), thrombocytopenia (low levels of platelets), neutropenia (low levels of neutrophils, a type of white blood cell that fights infection) and hyperlipaemia (high blood levels of a type of fat). 
Najpogostejši resni neželeni učinki zdravila Torisel so alergijske (preobčutljivostne ) reakcije , resne reakcije, do katerih pride med infundiranjem ali kmalu po njem, okužbe, bolezni pljuč, vključno s pljučnico (vnetjem pljuč) in pljučno embolijo (krvnim strdkom v pljučih), krvavitve v možganih, odpoved ledvic, perforacija (raztrganje) črevesja, zapleti pri celjenju ran, hiperglikemija (visoke ravni sladkorja v krvi), trombocitopenija (nizka raven trombocitov), nevtropenija (nizke ravni nevtrofilcev, vrste belih krvnih celic, ki se borijo proti okužbam) in hiperlipemija (visoke ravni vrste maščobe v krvi).
The active substance in Torisel, temsirolimus blocks a protein called ‘mammalian target of rapamycin' (mTOR). 
Zdravilna učinkovina zdravila Torisel, temsirolimus, deluje z zaviranjem beljakovine, imenovane „tarča rapamicina pri sesalcih“ (mTOR).
For mantle cell lymphoma, the recommended dose is 175 mg once a week for three weeks, followed by weekly doses of 75 mg. 
‑m iligram ski odm er limfomu plaščnih celic je priporočeni odmerek 175 mg enkrat na teden tri tedne, čemur sledijo
How is Torisel used? 
Kako se zdravilo Torisel uporablja?
• advanced renal cell carcinoma (a kidney cancer). 
• napredovalim karcinomom ledvičnih celic (rakom ledvic).
For the full list of side effects of Torisel, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Torisel, glejte navodilo za uporabo.
10 (10x1) vials (multi-pack) 
10 (10x1) vial (skupno pakiranje)
1 vial + 1 ampoule 
1 viala + 1 ampula
4 vials + 4 ampoules 
4 viale + 4 ampule
10 (10x 1+1) vials + ampoules (multi-pack) 
10 (10x 1+1) vial + ampul (skupno pakiranje)
Romania Alapis Romania s.r.l. 
Romunija Alapis Romania s.r.l.
LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATIONS, APPLICANTS IN THE MEMBER STATES 
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, PREDLAGATELJEV / IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
Bulgaria Alapis Bulgaria Ltd., 29, Atanas Dukov Str. 1407, Sofia, 
Bolgarija Alapis Bulgaria Ltd., 29, Atanas Dukov Str. 1407, Sofia,
Germany Alapis S.A., 2 Aftokratoros Nikolaou street, 17671 Athens, Greece 
Nemčija Alapis S.A., 2 Aftokratoros Nikolaou street, 17671 Athens, Greece
Belgium Alapis S.A., 2 Aftokratoros Nikolaou street, 17671 Athens, Greece 
Portugalska Alapis S.A., 2 Aftokratoros Nikolaou street, 17671 Athens, Greece
It must also not be used in breastfeeding mothers. 
Prav tako ga ne smejo uporabljati doječe matere.
It contains the active substance vinflunine (25 mg/l). 
Vsebuje zdravilno učinkovino vinflunin (25 mg/l).
The European Commission granted a marketing authorisation valid throughout the European Union for Javlor on 21 September 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Javlor, veljavno po vsej Evropski uniji, odobrila dne 21. septembra 2009.
‘Metastatic' means that the cancer has spread to other parts of the body. 
„Metastatski“ pomeni, da se je rak že razširil na druge dele telesa.
The full EPAR for Javlor can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Javlor je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
However, there was a difference among patients who fulfilled the strict criteria entry requirements for the study. 
Vendar pa je bilo opaziti razliko med bolniki, ki so izpolnjevali stroga merila za vključitev v študijo.
What benefit has Javlor shown during the studies? 
Kakšne koristi je zdravilo Javlor izkazalo med študijami?
It must not be used in patients who have or have had a severe infection within the past two weeks or in patients with a neutrophil count of less than 1,500 per mm for the first administration or less than 1,000/mm3 for subsequent administrations or a platelet count less than 100,000 per mm3. 
Ne sme se uporabljati pri bolnikih, ki imajo ali so v zadnjih dveh tednih imeli hudo okužbo, ali pri bolnikih s številom nevtrofilcev pod 1 500 na mm pri prvem odmerjanju zdravila oziroma manj kot 1 000/mm3 pri nadaljnjih odmerjanjih ali številom trombocitov pod 100 000
Other information about Javlor 
Druge informacije o zdravilu Javlor
During the study all patients received best supportive care (any medicines or techniques to help patients, but not other anticancer medicines). 
Med študijo so bili vsi bolniki deležni tudi najboljše podporne nege (katerih koli zdravil ali tehnik, ki bolnikom pomagajo, a ne vključujejo drugih zdravil proti raku).
The study also looked separately at the results in eligible patients who fulfilled strict criteria such as having had a worsening of the disease after treatment with a platinum-containing medicine. 
V študiji so ločeno proučevali tudi rezultate pri primernih bolnikih, ki so izpolnjevali določena stroga merila, na primer da se jim je bolezen po zdravljenju z zdravilom, ki vsebuje platino, poslabšala.
This is a summary of the European public assessment report (EPAR) for Javlor. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Javlor.
What is the risk associated with Javlor? 
Kakšna tveganja so povezana z zdravilom Javlor?
The CHMP decided that Javlor's benefits are greater than its risks and recommended that Javlor be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Javlor večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Javlor. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Javlor, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Treatment with Javlor should be started under the supervision of a doctor qualified to use anticancer medicines and is only given in specialised hospital units. 
Zdravljenje z zdravilom Javlor je treba začeti pod nadzorom zdravnika, ki je usposobljen za uporabo zdravil proti raku, daje pa se lahko samo v specializiranih bolnišničnih oddelkih.
The most common side effects with Javlor (seen in more than 1 patient in 10) are neutropenia, leucopenia (low white blood cell counts), anaemia (low red blood cell counts), thrombocytopenia (low platelet count), loss of appetite, constipation, abdominal (stomach) pain, vomiting, nausea (feeling sick), stomatitis (inflammation of the lining of the mouth), diarrhoea, alopecia (hair loss), myalgia (muscle pain), asthenia (weakness) or fatigue (tiredness), injection site reaction, fever and weight loss. 
Najpogostejši neželeni učinki zdravila Javlor (opaženi pri več kot 1 bolniku od 10) so nevtropenija, levkopenija (nizko število belih krvnih celic), slabokrvnost (nizko število rdečih krvnih celic), trombocitopenija (nizko število trombocitov), izguba teka, zaprtje, bolečine v trebuhu, bruhanje, slabost, stomatitis (vnetje ustne sluznice), driska, alopecija (izpadanje las), mialgija (bolečine v mišicah), astenija (šibkost) ali utrujenost, reakcije na mestu injiciranja, povišana telesna temperatura in izguba telesne mase.
The dose of Javlor to be given is based on the patient's body surface area (calculated using height and weight). 
Predpisani odmerek zdravila Javlor je odvisen od telesne površine bolnika (izračunane na podlagi višine in telesne mase).
In this group, those given Javlor lived for 6.9 months compared with 4.3 months for patients who were not given the Javlor. 
V tej skupini so bolniki, ki so prejemali zdravilo Javlor, živeli še 6,9 meseca, medtem ko so bolniki, ki zdravila Javlor niso prejemali, živeli še 4,3 meseca.
The doctor may need to adjust the dose by taking into account the patient's age, liver or kidney function and certain side effects that the patient may be experiencing. 
Zdravnik bo morda moral prilagoditi odmerek ob upoštevanju bolnikove starosti, delovanja jeter ali ledvic in nekaterih neželenih učinkov, ki bi se lahko pojavili pri bolniku.
In one main study of 370 adults with advanced or metastatic transitional cell carcinoma of the urothelial tract, patients who were given Javlor treatment were compared with patients who were not given any anticancer medicine. 
V glavni študiji s 370 odraslimi bolniki z napredovalim ali metastatskim prehodnoceličnim karcinomom urotelija so bolnike, ki so prejemali zdravilo Javlor, primerjali z bolniki, ki niso prejemali nobenega zdravila proti raku.
For more information about treatment with Javlor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Javlor preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The doctor may also delay or stop doses if the patient experiences certain side effects, including low levels of platelets and neutrophils (a type of white blood cell), and certain side effects affecting the heart, liver or lungs. 
Zdravnik lahko tudi odloži ali prekine odmerjanje, če se pri bolniku pojavijo nekateri neželeni učinki, vključno z nizkimi ravnmi trombocitov in nevtrofilcev (vrste belih krvničk), in določeni neželeni učinki, ki vplivajo na srce, jetra ali pljuča.
Why has Javlor been approved? 
Zakaj je bilo zdravilo Javlor odobreno?
Among all patients in the study, there was no clear evidence of a difference in survival between patients who received Javlor and those who did not. 
V študiji ni bilo jasnih dokazov o razliki v preživetju med bolniki, ki so prejemali zdravilo Javlor, in bolniki, ki ga niso prejemali.
Javlor must not be used in people who are hypersensitive (allergic) to vinflunine or other vinca alkaloids. 
Zdravila Javlor ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) vinflunin ali druge alkaloide rožnatega zimzelena.
Javlor is used for the treatment of adults with advanced or metastatic ‘transitional cell carcinoma of the urothelial tract' (a cancer that affects the lining of the bladder and the rest of the urinary tract). 
Zdravilo Javlor se uporablja za zdravljenje odraslih z napredovalim ali metastatskim „prehodnoceličnim karcinomom urotelija“ (rakom, ki prizadene steno sečnega mehurja in preostali del sečil).
All the patients had previously received treatment with a platinum-containing medicine which failed. 
Vsi bolniki so bili predhodno zdravljeni z zdravilom, ki vsebuje platino, vendar zdravljenje ni bilo uspešno.
The recommended dose is 320 mg per m2. Javlor is given as a drip into a vein over a period of 
Priporočeni odmerek je 320 mg na m2.
Javlor with best supportive care was more effective than best supportive care alone in prolonging the lives of patients with advanced or metastatic transitional cell carcinoma of the urothelial tract. 
Zdravilo Javlor v kombinaciji z najboljšo podporno oskrbo je bilo pri podaljšanju preživetja bolnikov z napredovalim ali metastatskim prehodnoceličnim karcinomom urotelija učinkovitejše od najboljše podporne oskrbe.
The active substance in Javlor, vinflunine, belongs to the group of anticancer medicines known as the vinca alkaloids. 
Zdravilna učinkovina v zdravilu Javlor, vinflunin, spada v skupino zdravil proti raku, znanih kot alkaloidi rožnatega zimzelena.
Javlor is used when previous treatment with a platinum-containing anticancer medicine has failed. 
Zdravilo Javlor se uporablja, kadar zdravljenje z zdravili proti raku, ki vsebujejo platino, ni bilo uspešno.
For the full list of all side effects reported with Javlor, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Javlor, glejte navodilo za uporabo.
It attaches to a protein in cells called ‘tubulin', which is important in the formation of the internal ‘skeleton' that cells need to assemble when they divide. 
Veže se na beljakovino v celicah, imenovano „tubulin“, ki ima pomembno vlogo pri tvorbi notranjega „ogrodja“, ki ga morajo celice zgraditi, ko se delijo Vinflunin ob vezavi na tubulin v rakastih celicah zaustavi tvorbo ogrodja, s čimer prepreči delitev in razmnoževanje rakastih celic.
Measures to prevent constipation, such as laxatives, are recommended after Javlor is given in the first week. 
Prvi teden po uporabi zdravila Javlor so priporočljivi tudi ukrepi za preprečevanje zaprtja, kot je npr. jemanje odvajal.
How has Javlor been studied? 
Kako je bilo zdravilo Javlor raziskano?
Javlor is a concentrate for solution for infusion (drip into a vein). 
Zdravilo Javlor je koncentrat za pripravo raztopine za infundiranje (kapalne infuzije v veno).
20 minutes once every three weeks. 
Zdravilo Javlor se dovaja 20 minut kot kapalna infuzija v veno enkrat na tri tedne.
What is Javlor used for? 
Za kaj se zdravilo Javlor uporablja?
This is because low levels of haemoglobin (a protein found in red blood cells that carries oxygen around the body) and blood cells (white blood cells and platelets) are frequent side effect of the medicine. 
Pred odmerjanjem zdravila Javlor je treba pri bolnikih s krvnimi preiskavami preveriti ravni krvničk in hemoglobina, ker sta nizki ravni hemoglobina (beljakovine v rdečih krvničkah, ki prenaša kisik po telesu) in krvničk (belih krvničk in trombocitov) pogosta neželena učinka zdravila.
How does Javlor work? 
Kako zdravilo Javlor deluje?
How is Javlor used? 
Kako se zdravilo Javlor uporablja?
Strength Pharmaceutical Form Route of Administration 
Farmacevtska oblika Način aplikacije
EU Number 
Številka EU Lastniško ime Jakost
The patients were treated for up to 23 months. 
Bolnice so zdravili do 23 mesecev.
The European Commission granted a marketing authorisation valid throughout the European Union for Forsteo on 10 June 2003. 
Evropska komisija je dovoljenje za promet z zdravilom Forsteo, veljavno po vsej Evropski uniji, izdala 10. junija 2003.
What measures are being taken to ensure the safe and effective use of Forsteo? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Forsteo?
The full EPAR for Forsteo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Forsteo je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Forsteo must not be used in children or in young adults whose bones are not yet fully mature, or during pregnancy or breastfeeding. 
Ne sme se uporabljati pri otrocih ali mlajših odraslih, katerih kosti še niso popolnoma razvite, oziroma med nosečnostjo ali dojenjem.
It also increases the absorption of calcium from food and prevents too much calcium being lost in the urine. 
Poleg tega poveča absorpcijo kalcija iz hrane in preprečuje izgubo velike količine kalcija v urinu.
It also reduced the risk of non-vertebral fractures by 62%, but did not reduce the risk of hip fractures. 
Hkrati je za 62 % zmanjšalo tveganje za nevretenčne zlome, vendar ni zmanjšalo tveganja za zlome kolka.
Forsteo has been studied in three main studies. 
Zdravilo Forsteo so raziskovali v treh glavnih študijah.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Forsteo have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila Forsteo, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The main measure of effectiveness was the number of new vertebral fractures at the end of the study, although the study also looked at non-vertebral fractures. 
Glavno merilo učinkovitosti je bilo število novih zlomov vretenc na koncu študije, čeprav so v študiji spremljali tudi nevretenčne zlome.
This is a summary of the European public assessment report (EPAR) for Forsteo. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Forsteo.
A user manual is available for the pen. 
Na voljo je priročnik za uporabo peresnika.
For more information about treatment with Forsteo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Forsteo preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
It is available as a solution for injection in prefilled pens (one 2.4 ml prefilled pen contains 600 micrograms of teriparatide). 
Na voljo je v obliki raztopine za injiciranje v napolnjenih injekcijskih peresnikih (eden 2,4-mililitrski napolnjeni injekcijski peresnik vsebuje 600 mikrogramov teriparatida).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Forsteo. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Forsteo must not be used in patients who have other bone diseases such as Paget's disease, bone cancer or bone metastases (cancer that has spread to the bone), patients who have had radiation therapy of the skeleton, or patients who have hypercalcaemia (high blood calcium levels), unexplained high levels of alkaline phosphatase (an enzyme) or severe kidney disease. 
Zdravilo Forsteo se ne sme uporabljati pri bolnikih, ki imajo druga obolenja kosti, kot so Pagetova bolezen, kostni rak ali metastaze v kosteh (rak, ki se je razširil na kosti), bolnikih, ki so bili na obsevanju okostja, ali bolnikih, ki imajo hiperkalciemijo (visoke ravni kalcija v krvi), tistih z nepojasnjeno visokimi ravnmi alkalne fosfataze (vrste encima) ali hudim obolenjem ledvic.
The study included 429 women and men who had osteoporosis and had been taking glucocorticoids for at least three months. 
V študijo je bilo vključenih 429 žensk in moških, ki so imeli osteoporozo in so najmanj tri mesece jemali glukokortikoide.
What benefit has Forsteo shown during the studies? 
Kakšne koristi je zdravilo Forsteo izkazalo med študijami?
The most common side effect with Forsteo (seen in more than 1 patient in 10) is pain in the arms or legs. 
Najpogostejši neželeni učinek zdravila Forsteo (opažen pri 1 bolniku od 10) so bolečine v rokah ali nogah.